Joseph G. Pressey · Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes
Follow
Article1 min read·Published Feb 2017Older

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Feb 2017 · 1 min read

In brief

In brief

Prospective genomic sequencing of 72 histiocytosis patients identified actionable mutations including BRAF V600E, MAP2K1 variants, and novel BRAF deletions resistant to standard inhibitors. Targeted therapies with dabrafenib or trametinib produced dramatic responses in refractory multisystem LCH cases, supporting routine genomic profiling at diagnosis.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Many patients with histiocytic disorders such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester disease (ECD) have treatment-refractory disease or suffer recurrences. Recent findings of gene mutations in histiocytoses have generated options for targeted therapies. We sought to determine the utility of prospective sequencing of select genes to further characterize mutations and identify targeted therapies for patients with histiocytoses. Biopsies of 72 patients with a variety of histiocytoses underwent comprehensive genomic profiling with targeted DNA and RNA sequencing. Fifteen patients (21%) carried the known BRAF V600E mutation, and 11 patients (15%) carried various mutations in MAP2K1, which we confirm induce constitutive activation of extracellular signal-regulated kinase (ERK) and were sensitive to inhibitors of mitogen-activated protein kinase kinase (MEK, the product of MAP2K1). We also identified recurring ALK rearrangements, and 4 LCH patients with an uncommon in-frame deletion in BRAF (N486_P490del or N486_T491>K), resulting in constitutive activation of ERK with resistance to V600E-specific inhibitors. We subsequently describe clinical cases where patients with aggressive multisystem LCH experience dramatic and sustained responses to monotherapy with either dabrafenib or trametinib. These findings support our conclusion that comprehensive genomic profiling should be regularly applied to these disorders at diagnosis, and can positively impact clinical care.

Statements in this article

  1. Biopsies of 72 patients with a variety of histiocytoses underwent comprehensive genomic profiling with targeted DNA and RNA sequencing.

    Research
  2. Fifteen patients (21%) carried the known BRAF V600E mutation.

    Research
  3. Eleven patients (15%) carried various mutations in MAP2K1, which induce constitutive activation of extracellular signal-regulated kinase (ERK) and were sensitive to inhibitors of mitogen-activated protein kinase kinase (MEK).

    Research
  4. Four LCH patients had an uncommon in-frame deletion in BRAF (N486_P490del or N486_T491>K), resulting in constitutive activation of ERK with resistance to V600E-specific inhibitors.

    Research
  5. Recurring ALK rearrangements were identified in histiocytoses.

    Research
  6. Patients with aggressive multisystem LCH experienced dramatic and sustained responses to monotherapy with either dabrafenib or trametinib.

    Research
  7. Comprehensive genomic profiling should be regularly applied to histiocytic disorders at diagnosis.

    Recommendation
  8. Comprehensive genomic profiling can positively impact clinical care in histiocytic disorders.

    Recommendation

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.